Today: 19 April 2026
Subscribe

London Stock Exchange at Record Highs – Inside the Historic Market’s Brexit Battle and 2025 Revival

UK Stock Market Today: FTSE 100 Falls as Reeves Tax U‑Turn Triggers Gilt Sell‑Off and Global Tech Jitters – 14 November 2025

The FTSE 100 fell 1.1% to 9,698.37 on Friday after reports that Chancellor Rachel Reeves scrapped plans to raise income tax in the upcoming Autumn Budget. Investors sold off UK government bonds, pushing the 10-year gilt yield up 13 basis points to 4.57%, and the pound dropped to around $1.31. The FTSE 250 lost 0.8%. Global tech weakness and concerns over China also weighed on sentiment.
14 November 2025
··
Interstellar Comet 3I/ATLAS Shrouded in CO₂ Fog – NASA’s SPHEREx Reveals a Cosmic Visitor’s Secrets

Interstellar Comet 3I/ATLAS on 14 November 2025: New ESA Orbit, Fresh Spectra, Politics, Alien Hype – and How to See It

The European Space Agency announced it has improved the orbit prediction for interstellar comet 3I/ATLAS using data from the ExoMars Trace Gas Orbiter. New optical and infrared images were released, while NASA faces criticism over withholding some images. The comet is now visible before dawn to Northern Hemisphere telescopes. Speculation about its origin continues.
14 November 2025
Vanguard’s Crypto U-Turn: $10T Giant Opens Doors to Bitcoin ETFs

Is Bitcoin the Biggest Speculative Bubble in History?

Tulip Mania in 1637 saw Dutch tulip bulb prices crash 99% after a rapid surge. The dot-com bubble burst in 2000, sending the NASDAQ down 78% and erasing trillions. U.S. home prices doubled before the 2007 housing crash, triggering the 2008 financial crisis. Bitcoin has also seen steep rises and crashes since its 2009 launch.
14 November 2025
Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest

Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest

Precigen shares surged nearly 30% intraday on November 14, trading around $4.90–$5.00 after reporting Q3 revenue of $2.92 million, far above expectations. The company’s PAPZIMEOS therapy for recurrent respiratory papillomatosis is fully launched in the U.S., with over 100 patients enrolled and broad insurance coverage. Precigen has also filed for European approval of PAPZIMEOS.
14 November 2025
···
Bitcoin Plunges Below $107K as Crypto Markets Reset – Experts See “Controlled” Dip

Bitcoin Price Today Plunges Below $96K as ETF Outflows, Fed Jitters and Liquidations Deepen Crypto Sell-Off – November 14, 2025

Bitcoin fell to a six-month low Friday, trading near $95,000–$96,000 after briefly topping $100,000 earlier in the day. The price is down about 22% from its October record above $126,000 and nearly 9% lower than a week ago. The global crypto market cap dropped to around $3.36 trillion, with 96 of the top 100 coins in decline.
14 November 2025
·
Figure Technology Solutions (FIGR) Soars 24% as Q3 2025 Earnings Beat and Tokenized Stock Plan Turbocharge Blockchain-Lending Story

Figure Technology Solutions (FIGR) Soars 24% as Q3 2025 Earnings Beat and Tokenized Stock Plan Turbocharge Blockchain-Lending Story

Figure Technology Solutions shares surged 24% Friday after reporting Q3 net revenue of $156 million, up 55% year over year, and net income of nearly $90 million, far above expectations. The company also filed for a tokenized share class to trade on its own platform. Consumer loan marketplace volume rose 70% to $2.5 billion. FIGR went public in September, raising $787.5 million.
14 November 2025
·····
Amaze Holdings (AMZE) Completes The Food Channel Acquisition; Plans Platform Revamp for Culinary Creators — Nov 12, 2025

Amaze Holdings (AMZE) Soars on Q3 2025 Earnings as Revenue Jumps 1,884% and Creator-Commerce Strategy Accelerates

Amaze Holdings reported Q3 2025 revenue of $1.25 million, up 1,884% from a year earlier, but posted a net loss of $5.15 million as expenses surged. The stock jumped over 50% intraday on heavy trading. Gross merchandise value reached $2.7 million, with about 12.2 million active creator storefronts and more than 350 million total visitors. The company ended the quarter with $0.3 million in cash, later raising $9.2 million.
14 November 2025
··
Warner Bros Discovery Stock Skyrockets on $60B Takeover Rumors

Warner Bros. Discovery (WBD) Stock Climbs as Paramount, Comcast and Netflix Line Up Bids in High‑Stakes Auction – November 14, 2025

Warner Bros. Discovery shares jumped as Paramount Skydance, Comcast, and Netflix prepared formal bids for all or parts of the company, sending the stock near a 52-week high around $23. Lawmakers raised antitrust concerns over a potential Netflix deal, while WBD revised CEO David Zaslav’s contract to address possible sale scenarios. First-round bids are due November 20. WBD’s market cap neared $55 billion.
14 November 2025
·····
Cypherpunk Technologies (LPTX → CYPH) Soars on Winklevoss‑Backed $50M Zcash Bet as Ticker Changes Today

Cypherpunk Technologies (CYPH) Soars After Zcash Pivot: What Investors Need to Know on November 14, 2025

Cypherpunk Technologies (CYPH), formerly Leap Therapeutics, surged 70–90% intraday to over $3.00 on November 14, with trading volume topping 200 million shares. The company rebranded and spent $50 million to buy about 1.25% of Zcash’s supply after a private placement led by Winklevoss Capital. CYPH’s stock saw extreme volatility, swinging over 100 percentage points during the session.
14 November 2025
··
Datavault AI (DVLT) Stock Skyrockets on AI Frenzy – Key Facts & Future Outlook

Datavault AI (DVLT) Sets Q3 2025 Earnings Date as Stablecoin Strategy and Meme Coin Dividend Energize Stock

Datavault AI Inc. shares surged Friday, trading in the mid-$1.70s on heavy volume after the company set its Q3 2025 earnings release for November 17. Analysts expect a Q3 loss of about $0.07 per share. A new company editorial cited Q2 revenue of $1.7 million, up 467% year-over-year, and projected 2025 revenue of $30–$50 million. Investors await updates on a $150 million investment agreement with Scilex.
14 November 2025
···
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Merck’s $9.2 Billion Bid Sends Cidara Therapeutics (CDTX) Soaring 105% on November 14, 2025

Merck said it will acquire Cidara Therapeutics for $221.50 per share in cash, valuing the deal at about $9.2 billion. The offer represents a 109% premium to Cidara’s last closing price and sent CDTX shares up more than 100%. Both companies’ boards approved the deal, which is expected to close in early 2026 pending regulatory clearance. Merck aims to secure Cidara’s lead flu-prevention drug, CD388.
14 November 2025
··
Alibaba Stock Soars on AI Frenzy – Can the Rally Last?

Alibaba (BABA) Stock Today, November 14, 2025: Price Slips as AI Push, Blockchain Deals and White House Memo Collide

Alibaba ADRs fell 3% to $154.97 in heavy trading Friday, despite new AI and fintech launches and a JPMorgan blockchain partnership. Shares swung between $154.08 and $162.61 as investors weighed mixed earnings signals and US national-security headlines. Year-to-date, BABA remains up nearly 90%. Market cap stands near $385 billion, with a P/E ratio around 18.
14 November 2025
····
Agentic AI Hits an Inflection Point: Enterprise ROI, Software Winners and New Risks – November 14, 2025

Agentic AI Hits an Inflection Point: Enterprise ROI, Software Winners and New Risks – November 14, 2025

On November 14, 2025, companies including BNY and Walmart reported measurable returns from deploying agentic AI, according to new research and industry deals. Major vendors such as Cisco and Salesforce announced products built around autonomous AI agents, while analysts warned of rising risks and the need for new security and oversight measures.
14 November 2025
····
BigBear.ai (BBAI) Stock Today: Cantor Hikes Target to $7 as Options Volume Surges – November 14, 2025

BigBear.ai (BBAI) Stock Today: Cantor Hikes Target to $7 as Options Volume Surges – November 14, 2025

BigBear.ai shares traded near $6.28 Friday afternoon, easing after a volatile week marked by heavy volume and sharp swings. Cantor Fitzgerald raised its 12-month price target to $7 and reiterated an Overweight rating, citing the Ask Sage acquisition and recent earnings. Options trading remained elevated, with open interest well above average. Year-to-date, BBAI is up over 40%.
14 November 2025
·
Rigetti Computing (RGTI) Stock Faces Quantum Reality Check: Cramer’s “Sell Half” Call, Bubble Fears and Q3 Fallout – 14 November 2025

Rigetti Computing (RGTI) Stock Faces Quantum Reality Check: Cramer’s “Sell Half” Call, Bubble Fears and Q3 Fallout – 14 November 2025

Rigetti Computing shares fell about 60% from their mid-October peak, trading between $23 and $27 on November 14 after a year of extreme volatility and a 2,000% surge. Jim Cramer advised investors to “sell half” their position, citing declining revenues and heavy losses. A Motley Fool article predicted quantum computing stocks could drop 50% or more in 2026.
14 November 2025
··
Intel Stock Today (INTC): Oregon Layoffs, AI Shake‑Up and Wall Street Re‑Think — 14 November 2025

Intel Stock Today (INTC): Oregon Layoffs, AI Shake‑Up and Wall Street Re‑Think — 14 November 2025

Intel shares hovered near $35.77 Friday after a 5% drop Thursday, triggered by OpenAI’s decision not to buy Intel chips and renewed doubts over its AI strategy. The company confirmed 669 layoffs in Oregon, following 2,500 job cuts this summer. CEO Lip-Bu Tan will now directly oversee Intel’s AI division after Chief AI Officer Sachin Katti left for OpenAI.
14 November 2025
·
Tripadvisor (TRIP) Stock Edges Higher as Mizuho Upgrade Backs Cost Cuts, Viator Merger and AI Pivot – November 14, 2025

Tripadvisor (TRIP) Stock Edges Higher as Mizuho Upgrade Backs Cost Cuts, Viator Merger and AI Pivot – November 14, 2025

Tripadvisor shares rose 1.5% to about $15.00 midday Friday after Mizuho upgraded the stock to “Neutral” and raised its price target to $17.00, citing an $85 million cost-cutting plan and a pivot toward its Experiences business. The move follows a 6.75% drop Thursday and comes amid layoffs, a planned Viator merger, and preparations to launch an AI-powered travel product.
14 November 2025
···
1 … 1,532 1,533 1,534 1,535 1,536 … 1,854

Stock Market Today

  • Ford, GM, Stellantis Stocks Rise in Week Ending April 17
    April 19, 2026, 9:06 AM EDT. Ford Motor Co., General Motors, and Stellantis posted stock gains for the week ending April 17, 2026. Ford's shares rose 6.1% to $12.87, General Motors increased 6.41% to $81.32, and Stellantis climbed 7.21% to $8.62. The Detroit Three automakers experienced notable stock price fluctuations during the week amid broader market dynamics. Investors responded to sector developments, including leadership changes at Ford, defense collaborations involving GM and Ford, and Stellantis' strong North American vehicle shipments. Market hours run from 9:30 a.m. to 4 p.m. Eastern Time, Monday through Friday.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 19.04.2026

19 April 2026
LIVEMarkets rolling coverageStarted: April 19, 2026, 12:00 AM EDTUpdated: April 19, 2026, 9:16 AM EDT Ford, GM, Stellantis Stocks Rise in Week Ending April 17 April 19, 2026, 9:06 AM EDT. **Ford Motor Co., General Motors, and Stellantis** posted stock gains for the week ending April 17, 2026. Ford's shares rose 6.1% to $12.87, General Motors increased 6.41% to $81.32, and Stellantis climbed 7.21% to $8.62. The Detroit Three automakers experienced notable **stock price fluctuations** during the week amid broader market dynamics. Investors responded to sector developments, including leadership changes at Ford, defense collaborations involving GM and Ford, and Stellantis'
Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Go toTop